Ticagrelor (Brilinta) Professional Samples Recalled, 1 Lot

Steven Stiles


May 26, 2017

WILMINGTON, DE — AstraZeneca has announced it is voluntarily recalling a single lot (#JB5047) of physician-sample bottles of its antiplatelet agent ticagrelor (Brilinta/Brilique) after a report that one such bottle contained pills of another drug[1].

Ticagrelor is widely used for secondary prevention in patients with acute coronary syndromes (ACS) and to reduce the risk of stent thrombosis after coronary intervention for ACS.

The recalled bottles are marked to contain eight tablets of ticagrelor 90 mg, which are round and yellow. The tainted bottle reportedly also contained tablets of lesinurad (Zurampic) 200 mg, which are oval-shaped and blue, also from AstraZeneca, and indicated as add-on therapy for patients with gout already on xanthine oxidase inhibitors, according to the company.

"AstraZeneca is notifying physicians by recall letter and is arranging for return of all recalled products," it said.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.